Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Document Type
- Journal article (14)
Language
- English (14)
Keywords
- radioligand therapy (4)
- CXCR4 (3)
- PSMA (3)
- prostate cancer (3)
- theranostics (3)
- C-X-C motif chemokine receptor 4 (2)
- PET (2)
- PET/CT (2)
- [68Ga]PentixaFor (2)
- endoradiotherapy (2)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- MIBG (1)
- NEC (1)
- NET (1)
- PRRT (1)
- PSA (1)
- PSMA-RADS (1)
- RADS (1)
- RLT (1)
- SARS-CoV-2 (1)
- SSTR-RADS (1)
- SUV (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F-PSMA-1007 (1)
- adrenocortical carcinoma (1)
- angiogenesis (1)
- blood flow (1)
- cardiac nerve (1)
- combination (1)
- fibroblast activation protein (1)
- flare phenomenon (1)
- hematotoxicity (1)
- immune infiltration (1)
- inflammation (1)
- late response (1)
- mRNA (1)
- machine learning (1)
- miRNA (1)
- molecular imaging (1)
- multiple myeloma (1)
- nephrotoxicity (1)
- neuroendocrine tumor (1)
- overall survival (1)
- papillary thyroid carcinoma (PTC) (1)
- peptide receptor radionuclide therapy (1)
- prediction (1)
- radioiodine (1)
- reporting and data system (1)
- selpercatinib (1)
- staging (1)
- standardized reporting system (1)
- statin (1)
- sympathetic nervous system (1)
- thyroid carcinoma (TC) (1)
- transcriptome (1)
- tumor microenvironment (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (14)
- Urologische Klinik und Poliklinik (5)
- Medizinische Klinik und Poliklinik I (4)
- Medizinische Klinik und Poliklinik II (3)
- Comprehensive Cancer Center Mainfranken (2)
- Pathologisches Institut (2)
- Center for Computational and Theoretical Biology (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer \(^{68}\)Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard \(^{18}\)F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent \(^{18}\)F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistochemical staining (IHC) of CXCR4 from PET-guided biopsies. \(^{68}\)Ga-Pentixafor visualized tumor lesions in 10/11 subjects, while \(^{18}\)F-FDG revealed sites of disease in all 11 patients. Although weak to moderate CXCR4 expression could be corroborated by IHC in 10/11 cases, \(^{18}\)F-FDG PET/CT detected significantly more tumor lesions (102 vs. 42; total lesions, n = 107; p < 0.001). Semi-quantitative analysis revealed markedly higher 18F-FDG uptake as compared to \(^{68}\)Ga-Pentixafor (maximum and mean standardized uptake values (SUV) and tumor-to-background ratios (TBR) of cancerous lesions, SUVmax: 12.8 ± 9.8 vs. 5.2 ± 3.7; SUVmean: 7.4 ± 5.4 vs. 3.1 ± 3.2, p < 0.001; and, TBR 7.2 ± 7.9 vs. 3.4 ± 3.0, p < 0.001). Non-invasive imaging of CXCR4 expression in NEC is inferior to the reference standard \(^{18}\)F-FDG PET/CT.